Search

Your search keyword '"Kay, Neil E."' showing total 1,125 results

Search Constraints

Start Over You searched for: Author "Kay, Neil E." Remove constraint Author: "Kay, Neil E." Language english Remove constraint Language: english
1,125 results on '"Kay, Neil E."'

Search Results

1. Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era: CHRONIC LYMPHOCYTIC LEUKEMIA

2. The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia

3. Defining precancer: a grand challenge for the cancer community

7. IκBε deficiency accelerates disease development in chronic lymphocytic leukemia

9. Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism

10. Relationship among three common hematological premalignant conditions

11. Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis

12. Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia

13. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS

15. Mortality Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis

16. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome

17. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL

20. GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity

22. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

25. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma

27. Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans

28. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

30. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib

32. Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

33. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia

35. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy

40. Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

42. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes

44. Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?

46. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia

47. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia

48. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations

49. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

Catalog

Books, media, physical & digital resources